In our search, the presence of EGFR amplification was correlated with TP53 mutation in both two cohorts, which indicated EGFR amplification arise relatively late and toward the end of the evolution of EGFR‐mutated adenocarcinoma, resulting in aggressive pathological characteristics (e.g., high‐grade‐component predominance and lymphatic metastases). The gene discussed is EGFR; the disease is adenocarcinoma.